The platform is being introduced to expand access to treatments for people living with chronic conditions
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Farxiga is expected to have such a strong influence on the market due to the impressive results
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated
